Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement · Source last updated 2025-06-26
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
30 days post-treatment, up to a total of 1 year
What was measured
Toxicity information recorded will include the type, severity, and the probable association with the study regimen. Tables will be constructed to summarize the observed incidence by severity and type of toxicity. Additional safety analyses may be performed to most clearly enumerate rates of toxicities and to further define the safety profile of Id or IRd combinations. Treatment-emergent events will be tabulated.
Groups in this outcome
Arm B (Ixazomib and Dexamethasone)
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
Dexamethasone: Given PO
Ixazomib: Given PO
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
Dexamethasone: Given PO
Ixazomib: Given PO
Lenalidomide: Given PO
Arm A (Ixazomib and Dexamethasone)
UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
Dexamethasone: Given PO
Ixazomib: Given PO
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Arm B (Ixazomib and Dexamethasone)
22
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
21
Arm A (Ixazomib and Dexamethasone)
27
Reported measurements
Agitation
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Altered Mental Status
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Anemia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Anxiety
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Ari
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Bone Pain
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Bp195/90
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Cardiopulmonary Arrest, Presumed
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Cellulitis
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Colitis
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Conjunctivitis
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Constipation
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Death-Multisystem Organ Failure
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Dehydration
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Diarrhea
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Dress Syndrome
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Dysphagia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Ecchymosis
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Edema
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Fatigue
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Gastrointestinal Bleed
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Generalized Weakness
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Hepatitis
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Hernia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Hyperglycemia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Hypertension
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Hyponatremia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Hypophosphatemia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Insomnia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Leucopenia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Lymphopenia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Nausea And Vomiting
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Neuropathy
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Neutropenia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Neutropenic Fever
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Pancytopenia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Pedestrian In Motor Vehicle Accident
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Pneumonia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
6
Not reported
Not reported
Not reported
Not reported
Rash
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Sepsis
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Sinus Tachycardia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Supraventricular Tachycardia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Thrombocytopenia
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
6
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Tremors
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Tumor Lysis Syndrome
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Upper Respiratory Infection
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
6
Not reported
Not reported
Not reported
Not reported
Urinary Tract Infection
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm B (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arm A (Ixazomib and Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
title
Agitation
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
title
Altered Mental Status
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
title
Anemia
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
title
Anxiety
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
0
title
Ari
categories
measurements
group Id
OG000
value
4
group Id
OG001
value
1
group Id
OG002
value
0
title
Bone Pain
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
title
Bp195/90
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
title
Cardiopulmonary Arrest, Presumed
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
0
title
Cellulitis
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
4
title
Colitis
categories
measurements
group Id
OG000
value
4
group Id
OG001
value
0
group Id
OG002
value
2
title
Conjunctivitis
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
title
Constipation
denoms
counts
group Id
OG000
value
22
group Id
OG001
value
21
group Id
OG002
value
27
units
Participants
description
Toxicity information recorded will include the type, severity, and the probable association with the study regimen. Tables will be constructed to summarize the observed incidence by severity and type of toxicity. Additional safety analyses may be performed to most clearly enumerate rates of toxicities and to further define the safety profile of Id or IRd combinations. Treatment-emergent events will be tabulated.
groups
description
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
Dexamethasone: Given PO
Ixazomib: Given PO
id
OG000
title
Arm B (Ixazomib and Dexamethasone)
description
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
Dexamethasone: Given PO
Ixazomib: Given PO
Lenalidomide: Given PO
id
OG001
title
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
description
UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
Dexamethasone: Given PO
Ixazomib: Given PO
Triangle